Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148220 | 0.88 | KMT2A (0.47) | KMT2AMEN1UCHL1NPC1USP30 | |
| SCHEMBL13148218 | 0.87 | NPC1 (0.48) | KMT2AMEN1UCHL1NPC1USP30 | |
| SCHEMBL12159691 | 0.85 | KLK7 (0.52) | KLK7PREPKMT2AMEN1UCHL1 | |
| SCHEMBL3390852 | 0.82 | CMA1 (0.49) | KLK7PREPKMT2AMEN1NPC1 | |
| SCHEMBL3390847 | 0.82 | CMA1 (0.49) | KLK7PREPKMT2AMEN1NPC1 | |
| SCHEMBL5248179 | 0.77 | KLK7 (0.56) | KLK7PREPKMT2AMEN1CTRB1 | |
| SCHEMBL13747280 | 0.77 | KLK7 (0.53) | KLK7PREPKMT2AMEN1NPC1 | |
| SCHEMBL5970730 | 0.77 | KLK7 (0.66) | KLK7PREPKMT2AMEN1FKBP1A | |
| SCHEMBL159104 | 0.77 | KLK7 (0.66) | KLK7PREPKMT2AMEN1FKBP1A | |
| SCHEMBL159105 | 0.77 | KLK7 (0.66) | KLK7PREPKMT2AMEN1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288562-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288562-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100233120-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-16 | — | — | US | disclosed |
| US-20100233120-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233120-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KLK7 3500/4885PREP 2563/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.